Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types

Contributed by: PR Newswire

Tags

Hengrui-Pharma-ASCO

More Like This

Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

PR Newswire associated0

Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting

Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress

Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting

Sarah Cannon Research Institute to Present Latest Cancer Research Insights at 2024 ASCO® Annual Meeting

Sarah Cannon Research Institute to Showcase Cancer Insights at 2025 ASCO® Annual Meeting

Sarah Cannon Research Institute Delivers Novel Oncology Research Insights through 155+ Accepted Abstracts & Presentations at the 2026 ASCO® Annual Meeting